Imiquimod for the treatment of basal cell or squamous cell carcinoma : a review of clinical effectiveness and cost-effectiveness /
The purpose of this review is to compare the clinical effectiveness and cost-effectiveness of imiquimod (IMQ) to other treatment modalities for the treatment of basal cell carcinoma (BCC) or squamous cell carcinoma (SCC). This report is the first in the series of three reports on IMQ. The following...
Saved in:
| Online Access: |
http://www.ncbi.nlm.nih.gov/books/NBK525601/ Full text |
|---|---|
| Main Authors: | , |
| Format: | Electronic eBook |
| Language: | English |
| Published: |
Ottawa (ON) :
Canadian Agency for Drugs and Technologies in Health,
2017
|
| Edition: | Version: 1.0. |
| Series: | Rapid response report (Canadian Agency for Drugs and Technologies in Health)
|
| Subjects: |
| Summary: | The purpose of this review is to compare the clinical effectiveness and cost-effectiveness of imiquimod (IMQ) to other treatment modalities for the treatment of basal cell carcinoma (BCC) or squamous cell carcinoma (SCC). This report is the first in the series of three reports on IMQ. The following two reports will be on actinic keratosis and genital warts. |
|---|---|
| Physical Description: | 1 online resource (1 PDF file (29 pages)) : illustrations. |
| Bibliography: | Includes bibliographical references. |
| ISSN: | 1922-8147 |
| Source of Description, Etc. Note: | Description based on online resource; title from PDF title page (viewed March 4, 2018). |
